NeoGenomics (NASDAQ:NEO) received a $22.00 price target from stock analysts at Benchmark in a note issued to investors on Thursday. The firm currently has a “buy” rating on the medical research company’s stock. Benchmark’s price objective would indicate a potential upside of 16.46% from the company’s current price. Other analysts also recently issued research reports […]

Full article